ReS19 T
Alternative Names: ReS19; ReS19-TLatest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator reMYND
- Class Antidementias; Small molecules
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Austria
- 30 May 2024 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by reMYND
- 28 Jan 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Belgium